Pulmonary vasodilator therapy as treatment for patients with a Fontan circulation: the Emperor’s new clothes?

PVRI Member Authors: Rolf Berger

Introduction

With great interest we read the recent article by Wang et al. in Pulmonary Circulation presenting a meta-analysis on the efficacy and safety of pulmonary vasodilator therapy in patients with a Fontan circulation.1We commend the authors with this thorough attempt to provide an overview of the available evidence on this important and controversial topic. The authors report that they have performed a meta-analysis of randomized controlled trials (RCTs) and conclude that pulmonary vasodilator therapy, although not reducing mortality, improves peak oxygen consumption (pVO2), hemodynamics, and 6-min walking distance (6MWD) and reduces NYHA functional class statistically significantly based on nine studies.

Read the full article online

Topics

Pulmonary Circulation
Vasoreactivity: Vasoconstriction and Vasodilatation

Authors

Floris-Jan S. Ridderbos, Quint A.J. Hagdorn, Rolf M.F. Berger

Published in:

Pulmonary Circulation Vol 8: No 4 cover image

December 2018

Pulmonary Circulation Vol 8: No 4

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg